VICTOR DUQUE SANTANA-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Clinical Genitourinary Cancer, Vol. 22, Núm. 1, pp. 56-66

  2. Is trimodal therapy the current standard for muscle-invasive bladder cancer?

    Actas Urologicas Espanolas

2023

  1. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer

    World Journal of Urology, Vol. 41, Núm. 12, pp. 3829-3838

  2. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors in Locally Advanced Rectal Cancer

    Oncology (Switzerland), Vol. 101, Núm. 6, pp. 349-357

  3. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  4. Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 718-732